Literature DB >> 25054764

Case for diagnosis.

Gustavo Ávila Maquiné1, Maria de Fátima Maroja1, Cristina Rabello Mesquita2, Petra Pereira de Sousa1, Patrícia Motta de Morais1, Carolina Talhari1.   

Abstract

We report the case of a 81-year-old female patient who had a two-year history of violet-colored erythematous tumors on both legs. Histopathological and immunohistochemical examinations confirmed the diagnosis of primary cutaneous large B-cell lymphoma, leg type. This rare, cutaneous lymphoma affects predominantly elderly females. Clinically, patients present with tumoral lesions on one or both legs (worst prognosis). Diagnosis is based on clinical, histopathological and immunohistochemical findings. The strong expression of BCL2, BCL6, MUM-1 and CD20, and the positivity for Ki67 antigen confirm the diagnosis. R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) is the most widely accepted treatment.

Entities:  

Mesh：

Year:  2014        PMID： 25054764      PMCID： PMC4148291          DOI： 10.1590/abd1806-4841.20142955

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN： 0365-0596            Impact factor:   1.896


  6 in total

1.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

2.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

Authors:  Laurie H Sehn; Jane Donaldson; Mukesh Chhanabhai; Catherine Fitzgerald; Karamjit Gill; Richard Klasa; Nicol MacPherson; Susan O'Reilly; John J Spinelli; Judy Sutherland; Kenneth S Wilson; Randy D Gascoyne; Joseph M Connors
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

3.  Primary cutaneous B-cell lymphoma in Nottinghamshire U.K.: prognosis of subtypes defined in the WHO-EORTC classification.

Authors:  E M Bessell; C E Humber; S O'Connor; J S E English; W Perkins; P D Dickinson; A N Patel
Journal:  Br J Dermatol       Date:  2012-09-05       Impact factor: 9.302

Review 4.  WHO-EORTC classification for cutaneous lymphomas.

Authors:  Rein Willemze; Elaine S Jaffe; Günter Burg; Lorenzo Cerroni; Emilio Berti; Steven H Swerdlow; Elisabeth Ralfkiaer; Sergio Chimenti; José L Diaz-Perez; Lyn M Duncan; Florent Grange; Nancy Lee Harris; Werner Kempf; Helmut Kerl; Michael Kurrer; Robert Knobler; Nicola Pimpinelli; Christian Sander; Marco Santucci; Wolfram Sterry; Maarten H Vermeer; Janine Wechsler; Sean Whittaker; Chris J L M Meijer
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

5.  Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases.

Authors:  Florent Grange; Marie Beylot-Barry; Phillipe Courville; Eve Maubec; Martine Bagot; Béatrice Vergier; Pierre Souteyrand; Laurent Machet; Sophie Dalac; Eric Esteve; Isabelle Templier; Emmanuel Delaporte; Marie-Françoise Avril; Caroline Robert; Stephane Dalle; Liliane Laroche; Michele Delaunay; Pascal Joly; Janine Wechsler; Tony Petrella
Journal:  Arch Dermatol       Date:  2007-09

Review 6.  Primary cutaneous diffuse large B-cell lymphoma, leg type: diagnostic considerations.

Authors:  Alexandra C Hristov
Journal:  Arch Pathol Lab Med       Date:  2012-08       Impact factor: 5.534
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.